Short course radiation and immunotherapy for rectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rectal cancer (adenocarcinoma) that is locally advanced, meaning it has grown into nearby tissues or lymph nodes but hasn't spread to distant organs.
- Your tumor is confirmed to be microsatellite stable (MSS) or mismatch repair proficient (pMMR).
- Your tumor is located within 10 cm from the anal verge (low or mid rectal cancer).
- You are generally active and able to care for yourself (ECOG performance status 0 or 1).
- You have adequate organ function, which will be checked through blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to treat mid- to low rectal cancer. The goal is to potentially improve outcomes while reducing side effects.
This trial tests a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.